Adenosine A2AR inhibition reversed working memory deficits of HD at early stages models and it was proposed that A2AR antagonists may therapeutically reverse the cognitive deficits in HD patients (Li W. et al., 2015). This evidence concerns the gene ADORA2A and Huntington disease.